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Background: Colorectal cancers (CRCs) detected through the NHS Bowel Cancer Screening Programme (BCSP) have been shown
to have a more favourable outcome compared to non-screen-detected cancers. The aim was to identify whether this was solely
due to the earlier stage shift of these cancers, or whether other factors were involved.
Methods: A combination of a regional CRC registry (Northern Colorectal Cancer Audit Group) and the BCSP database were used
to identify screen-detected and interval cancers (diagnosed after a negative faecal occult blood test, before the next screening
round), diagnosed between April 2007 and March 2010, within the North East of England. For each Dukes’ stage, patient
demographics, tumour characteristics, and survival rates were compared between these two groups.
Results: Overall, 322 screen-detected cancers were compared against 192 interval cancers. Screen-detected Dukes’ C and D CRCs
had a superior survival rate compared with interval cancers (P¼ 0.014 and P¼ 0.04, respectively). Cox proportional hazards
regression showed that Dukes’ stage, tumour location, and diagnostic group (HR 0.45, 95% CI 0.29–0.69, Po0.001 for screen-
detected CRCs) were all found to have a significant impact on the survival of patients.
Conclusions: The improved survival of screen-detected over interval cancers for stages C and D suggest that there may be a
biological difference in the cancers in each group. Although lead-time bias may have a role, this may be related to a tumour’s
propensity to bleed and therefore may reflect detection through current screening tests.
Colorectal cancer (CRC) is a major public health problem. Men
have a 1 in 16 and women have a 1 in 20 lifetime risk of being
diagnosed with CRC. In 2007–2008, there were B17 100 new cases
diagnosed in men and 14 400 in women, making it the third most
commonly diagnosed cancer (excluding non-melanoma skin
cancers) in the United Kingdom (UK). In the same year,
B13 300 people died from CRC, the second highest cause of
cancer mortality in the UK (Cancer Research UK, 2010).
The NHS Bowel Cancer Screening Programme (BCSP) was
introduced in April 2006 in order to decrease population mortality
from CRC. The primary aim of the programme is to detect CRC
at an earlier stage, thereby improving survival (NHS Cancer
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Screening Programmes, 2006). A secondary aim is to identify and
remove colorectal adenomas.
In the North East of England, full uptake of the screening
programme was achieved by April 2008. The population eligible
for screening included anyone aged 60–69 years, extended to 74
years in January 2010. Screening comprises biennial non-
rehydrated guaiac-based faecal occult blood tests (FOBt; Hema-
Screen, Immunostics Inc.). For those with positive results, a
colonoscopy is offered (NHS Cancer Screening Programmes,
2006). Those with a negative FOBt are re-invited to undergo
FOB testing in 2 years’ time.
We have previously reported a comparison of screen-detected and
interval CRCs diagnosed after a positive or negative BCSP FOB
testing, respectively (Gill et al, 2012). Interval CRCs (defined as a
cancer diagnosed after a negative screening episode, before the next
planned screening test) have been shown by this and other studies to
be more commonly found in women and to be located in the right
colon (Steele et al, 2011; Morris et al, 2012a). As nearly 40% of
screen-detected cancers are Dukes’ Stage A, it has been presumed that
it is the early tumour stage which influences the survival rate
compared with the interval cancer group. It is not known whether
interval cancers are de novo lesions following a true negative
screening test, or represent a false negative test or further investigation
of a ‘missed’ lesion (Cooper et al, 2012). Interval CRCs are more
frequently found in the right colon, and are often sessile, making
them harder to detect at colonoscopy (Harvey and Ruszkiewicz,
2007). However, interval CRCs are more likely than screen-detected
CRCs to have features of microsatellite instability (MSI), as a marker
of genetic instability. Lesions with MSI are associated with rapid
growth, and therefore may develop between examinations. To date,
studies investigating the biology of interval cancers have been based
on those detected in symptomatic populations (Sawhney et al, 2006;
Arain et al, 2010; Shaukat et al, 2010).
The aim of this study was to analyse survival after diagnosis of
individuals with a screen-detected CRC compared with individuals
with an interval CRC when matched for tumour stage.
MATERIALS AND METHODS
The Northern Region Colorectal Cancer Audit Group (NORC-
CAG) registry was interrogated to identify all patients diagnosed
with a CRC between 1 April 2007 and 31 March 2010, in the
screening age range of 60–69 years. These patients were cross-
referenced with the regional bowel cancer screening database to
obtain each patient’s screening history. Patients were then
categorised into their diagnostic category of either screen-detected
or interval CRCs.
The study was classed as a service evaluation, therefore formal
ethical approval was not required. The National Information
Governance Board (NIGB) accepted that pseudo-anonymisation of
patients between databases was sufficient for no formal approval to
be required.
American Society of Anaesthesiologists (ASA) physical status
grade was used as a surrogate for severity of patient’s comorbidity,
being dichotomised into grades 1–2 or 3–5 (data recorded in the
NORCCAG database, and supplemented where possible from
patient records). Tumour location was dichotomised as distal to
the splenic flexure or proximal (up to and including the splenic
flexure). Deprivation level was calculated using the participants’
postcode to derive their respective index of multiple deprivation
rank (2007) for the Lower Super Output Area that they reside in.
Patients were then grouped into their respective quintiles, from most
affluent to most deprived. The modified Dukes’ staging classification
(stages A–D) was used to stage each tumour. Local excisions
included all endoscopic polypectomies and trans-anal resection of
tumours. Management of all CRC cases were discussed in dedicated
colorectal multidisciplinary team meetings. No a priori statistical
analysis was performed, it was solely on the population within the
defined database. Pearson’s chi-squared tests were used for variables
of gender, deprivation, ASA grade, tumour location and Dukes’
stage. The log-rank Mantel–Cox test used for survival analysis, and
Cox proportional hazards regression for multivariate analysis.
Survival length was calculated from date of diagnosis to death, or
censored at the end of available follow-up (1 March 2012). Data
were analysed using SPSS version 19.0 (SPSS Inc., Chicago, IL,
USA). Significance was assumed at the 0.05 level.
RESULTS
Of 514 CRCs detected within the study period, 322 (67.6%) were
screen-detected and 192 (37.4%) were interval CRCs. All interval
cancers were diagnosed after an overall normal FOBt, with 15
(7.8%) interval cancers submitting one unclear FOB test first,
before having two normal tests. There were no post-colonoscopy
interval cancers. Mean survival length was 32.1 months (s.e.m. 0.59
months). Results are presented by modified Dukes’ stage, and are
shown in Table 1.
Outcomes for Dukes’ A cancers. One of 36 (2.8%) of Dukes’ A
interval cancers and 15 of 125 (12.0%) of screen-detected cancers
were diagnosed after the incident (second round) of FOB tests.
There were no significant differences found in tumour site, T stage,
patient comorbidity level, or deprivation level between interval and
screen-detected Dukes’ A cancers. Despite comparable T staging,
there were significantly more screen-detected CRCs managed with
local excision compared with interval CRCs (30.4% vs 11.1%).
Despite this, the 30-day mortality rate and overall survival rate (on
Kaplan–Meier analysis) were equivalent between screen-detected
and interval Dukes’ A CRCs (log-rank Mantel–Cox w2¼ 2.901,
df¼ 1, P¼ 0.089; Figure 1). However, there were only a small
number of deaths overall in each group.
Outcomes for Dukes’ B cancers. One of 51 (2.0%) of Dukes’ B
interval cancers and 9 of 81 (11.1%) of screen-detected cancers
were diagnosed after the incident (second round) of FOB tests.
When the demographics and tumour details of the Dukes’ B cancer
patients were reviewed, significant differences were found in the
mean age at diagnosis (t¼ 2.29, P¼ 0.023, although unlikely
clinically significant) and T stage (w2¼ 4.959, df¼ 1, P¼ 0.026),
both of which were greater in the interval cancer group (Table 1).
Gender, ASA grade, deprivation level, tumour site, management,
and 30-day mortality rate were not significantly different between
screen and interval cancer groups (Table 1).
The survival rates between the two groups was equivalent (log-
rank Mantel–Cox w2¼ 0.023, df¼ 1, P¼ 0.880; Figure 2), although
there were again only a small number of deaths in each group.
Outcomes for Dukes’ C cancers. Three of 56 (5.4%) of Dukes’ C
interval cancers and 10 of 89 (11.2%) of screen-detected cancers
were diagnosed after the incident (second round) of FOB tests.
Within the screen-detected cancer group, there were significantly
more men (w2¼ 5.486, df¼ 1, P¼ 0.019) and left-sided tumours
(w2¼ 4.723, df¼ 1, P¼ 0.030; Table 1). A greater proportion of
pT4 tumours were seen in the interval cancer group (37.5% vs
22.5%), although this and the overall T-stage proportions were not
significantly different between groups. There were no differences
found in the ASA grade, deprivation level, modality of surgery, or
30-day mortality between groups.
Patients with Dukes’ C screen-detected cancers had improved
survival compared to interval cancers (log-rank Mantel–Cox
w2¼ 6.048, df¼ 1, P¼ 0.014; Figure 3).
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When the proportions of C1 and C2 cancers between groups
were reviewed (screen-detected C1 89.9% vs interval C1 87.5%),
there were no significant differences found (w2¼ 0.2, df¼ 1,
P¼ 0.66). For Dukes’ C2 cancers and combined Dukes’ C, the
mean number of positive lymph nodes was significantly higher in
the interval cancer group compared to the screen-detected group,
as shown in Table 2.
When the survival curves were separated into Dukes’ C1 and C2
CRCs, tumour site, and gender, only screen-detected cancers of
Dukes’ C2 stage had a significantly superior survival curve
compared with the equivalent interval cancer group (w2¼ 9.449,
df¼ 1, P¼ 0.002).
Outcomes for Dukes’ D cancers. Two of 22 (4.5%) of Dukes’ D
interval cancers and 3 of 21 (14.3%) of screen-detected cancers
were diagnosed after the incident (second round) of FOB tests.
There were no differences in gender, ASA grade, tumour location,
or T stage observed between groups. There were significant
differences in deprivation level (w2¼ 12.044, df¼ 4, P¼ 0.017) and
rates of resective surgery (screen-detected 57.1% vs interval 22.7%,
w2¼ 7.792, df¼ 2, P¼ 0.020) between groups. Although 11.4% of
patients with an interval CRC died within the first 30 days post
diagnosis compared with none of the patients with a screen-
detected CRC, this was not statistically significant.
Survival for these groups was found to be significantly
different, with screen-detected cancers having a better survival
rate (log-rank Mantel–Cox w2¼ 8.322, df¼ 1, P¼ 0.04), as shown
in Figure 4.
Multivariate analysis across Dukes’ stages. Table 3 shows the
results of the Cox proportional hazards regression analysis of
variables influencing survival of patients. Dukes’ stage, tumour
location (HR 1.84, 95% CI 1.19–2.83, P¼ 0.006 for proximal
location) and diagnostic group (HR 0.45, 95% CI 0.29–0.69,
Po0.001 for screen-detected CRCs) were all found to have a
significant impact on the survival of patients.
DISCUSSION
This study reports a significant difference in survival between
screen-detected and interval cancer patients with Dukes’ C- and
D-stage CRCs. Previous research has suggested that the earlier
stage of screen-detected tumours is the explanation for the survival
advantage over interval cancers, but this study questions whether
this is the sole factor (Steele et al, 2011; Gill et al, 2012; Morris et al,
2012b). Of note, when compensating for stage of tumour on
multivariate analysis, there is still a large influence from the
diagnostic category, suggesting histological heterogeneity.
One compelling argument for the effects seen is that the results
are solely due to lead-time bias. In other words, that both cohorts
would have had the same survival outcome had they had been
diagnosed through symptomatic services. However, it is equally
plausible that there are biological differences between screen-
detected and interval cancers that make some tumours bleed more
readily and therefore be more likely to be detected by a FOBt.
Table 1. Patient demographics, tumour details, management and outcome of screen, and interval cancers by Dukes’ stage

















Mean age, years (s.e.m.) 64.75 (0.28) 65.80 (0.46) 64.88 (0.35) 65.99 (0.39) 65.49 (0.32) 65.77 (0.38) 64.05 (0.71) 65.24 (0.45)
Gender
Male 87 (69.6%) 20 (55.6%) 63 (77.8%) 34 (66.7%) 66 (74.2%) 31 (55.4%) 15 (71.4%) 29 (65.9%)
Female 38 (30.4%) 16 (44.4%) 18 (22.2%) 17 (33.3%) 23 (25.8%) 25 (44.6%) 6 (28.6%) 15 (34.1%)
ASA grade
1–2 70 (77.8%) 19 (73.1%) 51 (77.3%) 37 (78.7%) 65 (85.5%) 35 (77.8%) 9 (75.0%) 9 (52.9%)
3–5 20 (22.2%) 7 (26.9%) 15 (22.7%) 10 (21.3%) 11 (14.5%) 10 (22.2%) 3 (25.0%) 8 (47.1%)
Index of multiple deprivation quintile category
Most affluent 16 (12.8%) 10 (27.8%) 4 (4.9%) 8 (15.7%) 11 (12.4%) 9 (16.1%) 0 (0.0%) 3 (6.8%)
2 25 (20.0%) 3 (8.3%) 14 (17.3%) 6 (11.8%) 17 (19.1%) 11 (19.6%) 5 (23.8%) 5 (11.4%)
3 27 (21.6%) 9 (25.0%) 20 (24.7%) 15 (29.4%) 19 (21.3%) 15 (26.8%) 3 (14.3%) 13 (29.5%)
4 24 (19.2%) 6 (16.7%) 20 (24.7%) 10 (19.6%) 21 (23.6%) 12 (21.4%) 10 (47.6%) 7 (15.9%)
Most deprived 33 (26.4%) 8 (22.2%) 23 (28.4%) 12 (23.5%) 21 (23.6%) 9 (16.1%) 3 (14.3%) 16 (36.4%)
Tumour location
Distal to splenic flexure 108 (86.4%) 30 (83.3%) 54 (66.7%) 29 (56.9%) 69 (77.5%) 34 (60.7%) 16 (76.2%) 30 (68.2%)
Splenic flexure and proximal 17 (13.6%) 6 (16.7%) 27 (33.3%) 22 (43.1%) 20 (22.5%) 22 (39.3%) 5 (23.8%) 14 (31.8%)
T stage
pT1 86 (68.8%) 22 (61.1%) 6 (6.7%) 3 (5.4%) 0 (0.0%) 0 (0.0%)
pT2 39 (31.2%) 14 (38.9%) 11 (12.4%) 4 (7.1%) 1 (8.3%) 0 (0.0%)
pT3 70 (86.4%) 36 (70.6%) 51 (57.3%) 28 (50.0%) 5 (41.7%) 4 (40.0%)
pT4 11 (13.6%) 15 (29.4%) 20 (22.5%) 21 (37.5%) 6 (50.0%) 6 (60.0%)
pTx 1 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Type of procedure
Resective 87 (69.6%) 32 (88.9%) 81 (100.0%) 51 (100.0%) 89 (100.0%) 56 (100.0%) 12 (57.1%) 10 (22.7%)
Local excision 38 (30.4%) 4 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Palliative 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (14.3%) 8 (18.2%)
No procedure 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (28.6%) 26 (59.1%)
30-Day mortality
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.1%) 1 (1.8%) 0 (0.0%) 5 (11.4%)
No 125 (100.0%) 36 (100.0%) 81 (100.0%) 51 (100.0%) 88 (98.9%) 55 (98.2%) 21 (100.0%) 39 (88.6%)
Abbreviation: ASA¼American Society of Anaesthesiologists.
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Reasons for differences in bleeding tendency have been postulated
to be related to the extent of microerosion and a thin surface
epithelium of lesions in relation to their surface area (Uno and
Munakata, 1995), the location and overall size of the lesions
(Foutch et al, 1988) and, the degree of invasion through the
submucosa of malignant cells (Hirano et al, 1996). The FOB test
has also previously been shown to have differential detection rates
depending on location (but not stage) of cancer, as well as a dietary
influence (Macrae and John, 1982; Thomas et al, 1989).
Unfortunately, data relating to size and microscopic appearance
are not routinely collected by either the BCSP or NORCCAG
databases.
The timing of the FOBt is at a fixed point in relation to the age
of the screenee, but uptake of the test may be influenced if they
are experiencing lower GI symptoms, such as bleeding. Such
symptoms have been found to be prevalent among those under-
going a screening colonoscopy (Rajasekhar et al, 2012).
For Dukes’ C CRCs, no differences were found in the variables
known to influence outcome such as patient comorbidity (using
ASA grade as a surrogate), and deprivation level. All patients were
engaged in the screening programme, potentially eliminating any
difference in motivation or health behaviours. However, there was
a difference between male and female proportions, with a greater
proportion of men having a screen-detected cancer. The improved
survival curve of screen-detected cancers is therefore contrary to
the improved survival of women when adjusted for stage (Aravani
et al, 2009).
There are several possibilities in explaining the survival
difference observed for Dukes’ C CRCs. First, it may be due to
the difference in tumour location. There have been three recent
reports that have suggested that for left-sided colonic lesions,
survival is better for stage 3 cancer (American Joint Commission
on Cancer stage, with nodal involvement and worse for stage 2;
Time (months)
0 12 24 36 48
Interval
Number of deaths 2 3 1 0
Number at risk 51 49 44 18 1
Screen
Number of deaths 3 3 5 1


























Figure 2. Survival curve for screen-detected and interval cancers of
Dukes’ B stage.
Time (months)
0 12 24 36 48
Interval
Number of deaths 9 5 3 0
Number at risk 56 47 39 17 2
Screen
Number of deaths 3 6 4 0



























Figure 3. Survival curve for screen-detected and interval cancers of
Dukes’ C stage.
Time (months)
0 12 24 36 48
Interval
Number of deaths 2 0 0 0
Number at risk 36 34 31 8 1
Screen
Number of deaths 0 1 2 0






















0.00 12.00 24.00 36.00
Survival length (months)
48.00 60.00
Figure 1. Survival curve for screen-detected and interval cancers of
Dukes’ A stage.
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Meguid et al, 2008; Benedix et al, 2010; Weiss et al, 2011). As there
was a significantly greater proportion of left-sided cancers within
the screen-detected cancer group (78% vs 61%, P¼ 0.03), this may
explain the superior survival curve. Further evidence to support
this is that survival curves analysed by tumour site (for Dukes’ C
cancers) are not significantly different (right-sided P¼ 0.097, left-
sided P¼ 0.184).
Both groups had a similar mix of C1 and C2 stages but there
was only a significant difference in survival for C2 tumours
(P¼ 0.002). In the interval cancer group, for Dukes’ C2 cancers,
there was a significantly greater mean number of positive lymph
nodes found (15 vs 4). An explanation for this may be that this
subgroup of interval cancers was more aggressive in its regional
lymph node spread, which is in turn consistent with the poorer
outcomes for this group. This group may also have contained
tumours that were associated with adverse histological features
such as extramural lymphovascular invasion, tumour-associated
lymphocytes, or peritoneal involvement which the NORCCAG
database does not contain data upon (Shepherd et al, 1997;
Mitchard et al, 2010). Alternatively, lead-time bias would have
allowed more time for metastases for this subgroup to become
apparent.
An alternative explanation for differences in outcomes for each
stage of tumour, between interval and screen-detected groups is
that, instead of interval cancer group being more aggressive,
screen-detected cancers are more indolent than cancers detected
symptomatically pre-screening. Interval CRCs might be expected
to have a worse survival rate compared to a control group.
However, as previously reported, the survival curves for interval
cancers and control group cancers (non-screened population) are
equivalent (Gill et al, 2012). Therefore, the improved survival in
Table 2. Mean number of positive lymph nodes and total nodes harvested for each Dukes’ C stage
95% Confidence interval of
the difference




n¼49 Lower Upper t-Test, P-value
C1 Positive lymph nodes 2.9 (0.3) 3.6 (0.6)  0.63 2.05 0.293
Total lymph nodes 15.3 (0.8) 16.5 (1.2)  1.61 4.14 0.383
n¼9 n¼7
C2 Positive lymph nodes 3.9 (0.9) 14.6 (4.3) 2.25 19.12 0.017
Total lymph nodes 13.0 (1.6) 20.3 (5.1)  3.02 17.6 0.152
n¼89 n¼56
C combined Positive lymph nodes 3.0 (0.3) 5.0 (0.9) 0.43 3.53 0.013
Total lymph nodes 15.0 (0.7) 17.0 (1.3)  0.86 4.80 0.171
Time (months)
0 12 24 36 48
Interval
Number of deaths 25 10 2 0
Number at risk 44 19 8 2 0
Screen
Number of deaths 5 5 1 1

























Figure 4. Survival curve for screen-detected and interval cancers of
Dukes’ D stage.









Age (per year) 1.01 0.95 1.08 0.730
Sex
Female 1.00
Male 0.95 0.63 1.43 0.806
Diagnostic category
Interval 1.00
Screen-detected 0.45 0.29 0.69 o0.001
Index of multiple deprivation quintile category
Most affluent 1.00
2 0.75 0.29 1.92 0.549
3 1.02 0.44 2.34 0.962
4 1.78 0.79 4.02 0.168
Most deprived 2.01 0.92 4.40 0.079
ASA grade
ASA 1–2 1.00
ASA 3–5 1.56 0.90 2.72 0.114
Tumour site
Distal to splenic flexure 1.00
Splenic flexure and proximal 1.84 1.19 2.83 0.006
Dukes’ stage
Dukes’ A 1.00
Dukes’ B 3.85 1.41 10.54 0.009
Dukes’ C 6.51 2.49 16.97 o0.001
Dukes’ D 35.30 13.57 91.87 o0.001
Abbreviation: ASA¼American Society of Anaesthesiologists.
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the screen-detected group could be secondary to these tumours
having a low potential for metastasis, and hence reducing the risk
of a patient having micro-metastases or circulating tumour cells
remaining in situ after initial cancer treatment.
Limitations of this research are in the subgroup analysis of C1
and C2 CRC groups, where small numbers make it difficult to draw
any firm conclusions. The NORCCAG database does not contain
data on the management of metastases of patients that present with
Dukes’ D cancer. It is therefore not known whether there was a
difference in resection rate for metastases between the two groups.
If there was a higher rate of resection in the screen-detected group
this might, at least partially, explain the survival advantage. Data
regarding prior endoscopic treatment outwith the screening
programme were not available. Although, it is likely that all study
patients have had no previous endoscopic experience, as those who
are enrolled on a surveillance programme are asked to discuss this
with the programme (NHS Cancer Screening Programmes, 2006).
It is unknown whether the above results will be reproduced
with the introduction of endoscopic screening, such as flexible
sigmoidoscopy screening in the UK. However, a US study has
shown similar findings with improved survival rates for patients
detected through screening colonoscopy (Amri et al, 2013). The
implications of a biological difference in screen-detected cancers
may influence future screening strategies that are based upon a
tumour’s propensity to bleed, against those that endoscopically
screen a population.
The relationship between lead-time bias vs a difference in the
biology of screen-detected and interval CRCs and the outcome of
patients remains unknown, therefore a further detailed analysis of
the biology of screen and post FOBt interval cancers is planned.
This will help to answer questions regarding the nature
and structure of these cancers, both on a macroscopic and
microscopic level.
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